Skip to contentP
Protagenic Therapeutics, Inc.\new
P
PTIXProtagenic Therapeutics, Inc.\new Q3 2026 · 10-Q
Revenue$0.00$0.00derivedno prior Q3 2025 on file Net Income$2.21M$2.21Mno prior Q3 2025 on file EPS Diluted$1.14$1.14no prior Q3 2025 on file Operating Income-$925,103—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR
Operating Cash Flowderived-$509,667— ended Dec 31, 2025 · filed Mar 9, 2026 · 68 d after period end